DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer
Open Access
- 20 November 2014
- journal article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 15 (12) , 1658-1666
Abstract
Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still needed. One strategy to improve the effectiveness of TRAIL-based therapies is to specifically target one of the 2 cell death inducing TRAIL-receptors, TRAIL-R1 or TRAIL-R2 to overcome resistance. To this end, we designed constructs expressing soluble TRAIL (sTRAIL) variants that were rendered specific for either TRAIL-R1 or TRAIL-R2 by amino acid changes in the TRAIL ectodomain. When we expressed these constructs, including wild-type sTRAIL (sTRAILwt), TRAIL-R1 (sTRAILDR4) and TRAIL-R2 (sTRAILDR5) specific variants, in 293 producer cells we found all to be readily expressed and secreted into the supernatant. These supernatants were subsequently transferred onto target cancer cells and apoptos...Keywords
This publication has 62 references indexed in Scilit:
- Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAILMolecular & Cellular Proteomics, 2012
- Unraveling the Binding Mechanism of Trivalent Tumor Necrosis Factor Ligands and Their ReceptorsMolecular & Cellular Proteomics, 2011
- Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variantsCell Death & Disease, 2010
- TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5Journal of Molecular Medicine, 2010
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerBritish Journal of Cancer, 2010
- Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic CancerCancer Research, 2009
- Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic CarcinomaCancer Research, 2009
- Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2Molecular and Cellular Biology, 2006
- TRAIL-Induced Apoptosis and Gene Induction in HaCaT Keratinocytes: Differential Contribution of TRAIL Receptors 1 and 2Journal of Investigative Dermatology, 2003
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999